Vicore Pharma Holding AB American Depositary Shares (VCRE) Stock Price

VCREStock

$11.31−2.04%52W

Market Cap$318.41M

P/E—

PEG Ratio—

Div yield—

Beta0.75

VCRE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.20%

Price vs S&P 500 (4W)-3.21%

VGM Score28.83

Book Value / Share (Quarterly)$0.37

P/TBV (Annual)2.90x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)-19.19%

Gross Margin (TTM)360.27%

Net Profit Margin (TTM)-13454.92%

EPS (TTM)$-0.20

10-Day Avg Trading Volume0.75M

EPS Excl Extra (TTM)$-0.20

EPS (Annual)$-0.21

ROI (Annual)-43.59%

Gross Margin (Annual)197.14%

Net Profit Margin (5Y Avg)-4482.38%

Cash / Share (Quarterly)$0.39

Revenue Growth QoQ (YoY)-32.51%

ROA (Last FY)-39.18%

Revenue Growth TTM (YoY)-41.17%

EBITD / Share (TTM)$-0.20

ROE (5Y Avg)-60.78%

Operating Margin (TTM)-13742.16%

Cash Flow / Share (Annual)$-0.14

P/B Ratio3.49x

P/B Ratio (Quarterly)2.82x

Net Income / Employee (Annual)$-1,344,785

EV / Revenue (TTM)873.63x

Net Interest Coverage (TTM)-18.08x

ROA (TTM)-45.86%

EPS Incl Extra (Annual)$-0.21

Current Ratio (Annual)10.28x

Quick Ratio (Quarterly)12.57x

3-Month Avg Trading Volume0.67M

52-Week Price Return-2.04%

Revenue / Employee (TTM)$9,931

Tangible BV / Share (Quarterly)$0.41

P/S Ratio (Annual)906.13x

Asset Turnover (Annual)0.00x

52-Week High$1.90

Operating Margin (5Y Avg)-5120.17%

EPS Excl Extra (Annual)$-0.21

Tangible BV CAGR (5Y)31.02%

26-Week Price Return1.73%

Quick Ratio (Annual)9.99x

13-Week Price Return-9.57%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.69x

Enterprise Value$321.10M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-7.89%

Revenue / Employee (Annual)$10,754

Pretax Margin (Annual)-12509.14%

Cash / Share (Annual)$0.43

3-Month Return Std Dev60.52%

Gross Margin (5Y Avg)117.02%

Net Income / Employee (TTM)$-1,336,563

ROE (Last FY)-43.59%

Net Interest Coverage (Annual)-12.20x

EPS Basic Excl Extra (Annual)$-0.21

Receivables Turnover (TTM)8.08x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.20

Receivables Turnover (Annual)0.98x

ROI (TTM)-50.04%

P/S Ratio (TTM)980.63x

Pretax Margin (5Y Avg)-4482.43%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.41

Price vs S&P 500 (52W)-20.60%

Year-to-Date Return-6.37%

5-Day Price Return-0.19%

EPS Normalized (Annual)$-0.21

ROA (5Y Avg)-53.34%

Net Profit Margin (Annual)-12509.14%

Month-to-Date Return-4.86%

Cash Flow / Share (TTM)$-0.31

EBITD / Share (Annual)$-0.20

Operating Margin (Annual)-11851.87%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-60.77%

EPS Basic Excl Extra (TTM)$-0.20

P/TBV (Quarterly)2.90x

P/B Ratio (Annual)2.90x

Pretax Margin (TTM)-13452.48%

Book Value / Share (Annual)$0.41

Price vs S&P 500 (13W)-11.53%

Beta0.75x

Revenue / Share (TTM)$0.00

ROE (TTM)-50.04%

52-Week Low$0.90

vGradeF

gGradeF

mGradeC

vgmGradeD

VCRE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.31

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
VCREVicore Pharma Holding AB American Depositary Shares	F	F	C	$11.31
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.